iCAD (NASDAQ:ICAD) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of iCAD (NASDAQ:ICAD) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

iCAD Stock Performance

Shares of ICAD stock opened at $3.20 on Friday. The company has a market cap of $84.93 million, a PE ratio of -24.62 and a beta of 1.40. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The stock’s fifty day moving average price is $2.03 and its two-hundred day moving average price is $1.75.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Essex LLC bought a new stake in shares of iCAD in the 3rd quarter valued at $216,000. waypoint wealth counsel boosted its stake in iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after acquiring an additional 4,400 shares during the last quarter. Finally, Summit Trail Advisors LLC bought a new stake in shares of iCAD in the fourth quarter valued at $214,000. 24.61% of the stock is owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.